The effect of intermittent fasting diet on fatty liver

The effects of intermittent fasting diet in comparison with low calorie diet on lipid profile, glycemic status and liver fibrosis in patients with non-alcoholic fatty liver

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170202032367N5

Enrollment

Registered

2022-03-05

Start date

2022-04-21

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: In the intervention group, an intermittent fasting diet of the type (16: 8) will be used, in which individuals are allowed to receive only water and non-energy drin

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age 50-20 years Body mass index 25 - 30 kg/m2 Both genders Diagnosis of osteohepatitis based on Cap-score> 263 subjects with hepatic fibrosis based on Metavir-score = F2 Willingness to cooperate

Exclusion criteria

Exclusion criteria: Consumption of alcohol Other acute and chronic liver diseases Autoimmune diseases, kidney diseases, biliary diseases, diabetes, cancer Pregnancy and lactation Use of hepatotoxic drugs (phenytoin, lithium, tamoxifen, antibiotics), weight loss drugs, sage and corticosteroids Follow a special diet in the last three months

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Glucose oxidase enzymatic method using commercial kits of Pars Azmoon company in terms of (mg/dL).;Total cholesterol. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of total cholesterol level using Pars Azmoon kits and auto analyzer.;Triglyceride. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of triglyceride level using Pars Azmoon kits and auto analyzer.;HDL cholesterol. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of HDL cholesterol level using Pars Azmoon kits and auto analyzer.;LDL cholesterol. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of LDL cholesterol by Friedwald formula [LDL = Chol - (TG / 5 + HDL)], with plasma triglyceride concentrations below 400 mg/dL.;Aspartate transaminase enzyme (AST). Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Proposed IFCC method - Photometry Pars azmoon Kit.;Alanin transaminase enzyme (ALT). Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Proposed IFCC method - Photometry Pars azmoon Kit.;Gamma glutamyl transferase enzyme (GGT). Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Calorimetric-kinetic method proposed by IFCC.;Steatosis. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Fibroscan.;Hepatic fibrosis. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Fibroscan.;Fasting blood insulin level. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measuremen	—

Measure

Time frame

Fasting blood sugar. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Glucose oxidase enzymatic method using commercial kits of Pars Azmoon company in terms of (mg/dL).;Total cholesterol. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of total cholesterol level using Pars Azmoon kits and auto analyzer.;Triglyceride. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of triglyceride level using Pars Azmoon kits and auto analyzer.;HDL cholesterol. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of HDL cholesterol level using Pars Azmoon kits and auto analyzer.;LDL cholesterol. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Measurement of LDL cholesterol by Friedwald formula [LDL = Chol - (TG / 5 + HDL)], with plasma triglyceride concentrations below 400 mg/dL.;Aspartate transaminase enzyme (AST). Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Proposed IFCC method - Photometry Pars azmoon Kit.;Alanin transaminase enzyme (ALT). Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Proposed IFCC method - Photometry Pars azmoon Kit.;Gamma glutamyl transferase enzyme (GGT). Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Calorimetric-kinetic method proposed by IFCC.;Steatosis. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Fibroscan.;Hepatic fibrosis. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measurement: Fibroscan.;Fasting blood insulin level. Timepoint: At the beginning and end of the study (after 12 weeks (84 days)). Method of measuremen

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossien Imani

Tehran University of Medical Sciences

h_imani@sina.tums.ac.ir0098 21 889900285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026